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  Tetrandrine (TET), a bis-benzylisoquinoline alkaloid from 
the root of Stephania tetrandra, is known to have anti-tumor 
activity in various malignant neoplasms. However, the precise 
mechanism by which TET inhibits tumor cell growth remains 
to be elucidated. The present studies were performed to 
characterize the potential effects of TET on phosphoinositide 
3-kinase/Akt and extracellular signal-regulated kinase (ERK) 
pathways since these signaling pathways are known to be 
responsible for cell growth and survival. TET suppressed cell 
proliferation and induced apoptosis in A549 human lung 
carcinoma cells. TET treatment resulted in a down-regulation 
of Akt and ERK phosphorylation in both time-/concentration- 
dependent manners. The inhibition of ERK using PD98059 
synergistically enhanced the TET-induced apoptosis of A549 
cells whereas the inhibition of Akt using LY294002 had a less 
significant effect. Taken together, our results suggest that 
TET: i) selectively inhibits the proliferation of lung cancer 
cells by blocking Akt activation and ii) increases apoptosis by 
inhibiting ERK. The treatment of lung cancers with TET may 
enhance the efficacy of chemotherapy and radiotherapy and 
increase the apoptotic potential of lung cancer cells.
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Introduction
Apoptosis, also called programmed cell death, is essential 
for the homeostasis of normal tissues. Altering the level of 
apoptosis is involved in various diseases including cancer, 
viral infections, autoimmune diseases, neurodegenerative 
disorders and AIDS [22]. Therefore, controlling the 
apoptotic process may provide a critical leverage point for 
the treatment of various diseases.
Akt, also named protein kinase B, is known to be a critical 
target for cancer intervention. It is activated downstream of 
phosphoinositide 3-kinase (PI3K) by phosphorylation on 
two regulatory residues, Thr-308 and Ser-473 [3]. The 
activation of Akt plays a critical role in fundamental 
cellular functions such as cell proliferation and survival by 
phosphorylating a variety of substrates. Constitutively 
active Akt results in augemented resistance against 
apoptotic cellular insults, such as growth factor deprivation, 
UV irradiation or loss of matrix attachment [15]. Akt 
activation is found in many types of human tumors 
including breast cancer, lung cancer, melanoma and 
leukemia [7,16]. 
Extracellular signal-regulated kinase (ERK)1/2 is also 
crucial molecule in cell proliferation and carcinogenesis. It 
is activated by dual phosphorylation on both Thr202 and 
Tyr204 residues. Activated ERK1/2 has been reported in a 
variety of human tumor cell lines [8] and epithelial cancer 
tissues such as breast [1], kidney [17], colon [20], head and 
neck [2] and small-and non-small-cell lung cancer [4]. In 
many cases, ERK activation protects cells from drug- 
induced cell death [21]. A number of studies have indicated 
that the phosphorylation of ERK promotes cell survival by 
inhibiting apoptosis under various pathological conditions 
[5].
Tetrandrine (TET), a bis-benzylisoquinoline alkaloid from 
the root of Stephania tetrandra, has been used in China for 
several decades for the treatment of arthritis, arrhythmia, 
inflammation and silicosis [18]. TET was also reported to 
inhibit cellular proliferation in various cancer cell types 
[14]. However, the precise mechanisms by which TET 
inhibits tumor cell growth remain to be elucidated. In this 
study, therefore, we investigated the effects of tetrandrine 
on PI3K/Akt and ERK pathways in A549 human lung 
carcinoma cells. Here, we report that TET-induced apoptosis 
is closely associated with Akt-ERK crosstalk. 24    Hyun Sun Cho et al.
Materials and Methods
Reagents
TET was purchased from Sigma-Aldrich (USA). Anti- 
Bid, anti-Bax, anti-Bcl-xL, anti-Akt, anti-phospho-Akt 
Thr-308, Ser-473, anti-ERK and anti-phospho-ERK 
antibodies for Western blot analysis were purchased from 
Santa Cruz Biotechnology (USA). All reagents used in this 
study were reagent grade or better.
Cell culture and treatment
A549 human lung carcinoma cells were obtained from 
American Type Culture Collection (USA) and grown in 
RPMI-1640 medium supplemented with 10% fetal bovine 
serum (FBS; Hyclone Lab, USA). Cells were incubated at 
37
oC in a humidified atmosphere with 5% CO2. For TET 
treatment, cells were plated at a density of 2 × 10
6 cells per 
T-75 cm
2 culture flask, stabilized for 24 h and then treated 
with TET for the times and concentrations indicated. TET 
was dissolved in DMSO (Sigma-Aldrich, USA) at 20 mM 
as a stock solution and diluted for further analysis.
The concentration-dependent effect of TET on the 
inhibition of A549 cell proliferation
The impact of TET on the viability and proliferation of 
A549 cells was determined using the (3-[4,5-dimethylthiazol- 
2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 
cells were plated in 96-well culture plates (5 × 10
4 cells/well). 
After 24 h incubation, the cells were treated with TET (0, 
5, 10, 20, 30, 40, 50 or 60 μM) for the indicated times. After 
treatment, 10 μl of MTT solution (1 mg/ml in PBS) were 
added to each well and the plate was incubated for 4 h at 37
oC. 
To achieve solubilization of the formazan crystal formed in 
viable cells, 100 μl of DMSO were added to each well. The 
plate was shaken for 15 min at room temperature and the 
absorbance was measured using a microplate reader 
(Bio-Rad, USA) at a wavelength of 595 nm. 
Western blot analysis
Protein concentration was determined using a Bradford 
analysis kit (Bio-Rad, USA). Equal amounts of protein 
were separated on a 12% SDS polyacrylamide gel and 
transferred to a nitrocellulose membrane (Hybond ECL; 
Amersham Pharmacia, USA). The blots were blocked for 2 
h at room temperature with blocking buffer (10% nonfat 
milk in TTBS buffer containing 0.1% Tween 20). The 
membrane was incubated at room temperature for 1 h with 
specific antibodies. The antibodies were used at 1 : 1,000 
dilutions as specified by the manufacturer. After washing 
with TTBS, the membrane was incubated with a horseradish 
peroxidase-labeled secondary antibody and visualized 
using the Westzol enhanced chemiluminescence detection 
kit (Intron, Korea). The bands were detected with LAS- 
3000 (Fujifilm, Japan).
Flow cytometric detection of apoptosis
The percentage of apoptotic cells was determined by 
staining cells with annexin V-FITC and propidium iodide 
(PI). The annexin V-FITC apoptosis detection kit was 
purchased from Calbiochem (Canada). After incubation, 
cells were transferred to a microfuge tube, washed with 
ice-cold PBS, then resuspended in 0.5 ml cold × 1 binding 
buffer, followed by the addition of 1.25 μl of annexin 
V-FITC. The mixture was incubated at room temperature 
for 15 min in the dark. After adding PI, the samples were 
analyzed by FACS Calibur Flowcytometry (Becton 
Dickinson, USA).
Selective inhibitor study
The mitogen-activated protein kinase kinase (MEK1/2) 
inhibitor PD98059 and PI3K inhibitor LY294002 were 
purchased from Tocris (USA) and Calbiochem (Germany), 
respectively. Stock solutions were prepared in DMSO. The 
highest concentration of DMSO used was 0.2%. For the 
co-treatment experiments using TET and an inhibitor, cells 
were preincubated with either PD98059 (50 μM) or 
LY294002 (20 μM) for 1 h prior to TET treatment.
Statistical analysis
Result are shown as the mean ± SE. Statistical analyses 
were performed following ANOVA (MS-Excel 2003; 
Microsoft, USA) for multiple comparisons or Student’s 
t-test when the data consisted of only two groups. The 
differences between groups were considered significant at 
p ＜ 0.05 and  p ＜ 0.01 as indicated.
Results
To determine the effects of TET on cell viability, the MTT 
assay was performed on A549 cells treated with various 
concentrations of TET. The cells were exposed to 0-60 μM 
of TET for 24 h and 48 h. TET treatment significantly 
reduced the rate of cell proliferation compared to that of 
control cells in both time-/concentration-dependent manners. 
The reduction of cell proliferation and thus cell viability 
following treatment with 30 μM TET was roughly 59% at 
24 h (Fig. 1A) and 43% at 48 h (Fig. 1B). These results led 
us to use 30 μM of TET for further studies.
Since the MTT assay is a measure of total cell numbers 
and the results reflect changes in both cell proliferation as 
well as apoptosis, we next characterized the specific effects 
of TET on levels of apoptosis. To do this, a flowcytometric 
detection method was used after cells were treated with 30 
μM TET for 12 h and 24 h. The lower right quadrant 
(Annexin V positive and PI negative) represents the 
percentage of apoptotic cells with preserved plasma 
membrane integrity whereas the upper right quadrant 
(Annexin V positive and PI positive) refers to necrotic or 
apoptotic cells with a loss of plasma membrane integrity. It Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells    25
Fig. 1. The effect of tetrandrine on the proliferation of A549 cells.
The viability of A549 cells was measured using the MTT assay. 
The cells were incubated with increasing concentrations of 
tetrandrine for (A) 24 h or (B) 48 h. Data are presented as mean 
± SE of 3 independent experiments. *p ＜ 0.05, **p ＜ 0.01.
Fig. 2. Flowcytometric detection of apoptosis of A549 cells 
treated with tetrandrine (TET). Cells were incubated with 30 μM
of TET for 12 h and 24 h. (A) Control, (B) TET 12 h (C) TET 24
h, (D) Percentage of apoptotic cells from the time-dependent 
study. *p ＜ 0.05, **p ＜ 0.01.
Fig. 3. The effect of tetrandrine (TET) on the levels of pro- and 
anti-apoptotic proteins in A549 cells. Cells were treated with (A)
various concentrations (0, 10, 20 and 30 μM) of TET for 24 h or
(B) 30 μM of TET for indicated times (0, 2, 4, 8, 12 and 24 h).
was determined that most cells were alive since untreated 
cells were not stained with Annexin V or PI (Figs. 2A-C). 
The apoptotic fraction of cells treated with TET is 
represented in Fig. 2D. Treatment with TET caused 
apoptosis in a time-dependent manner; approximately 0.42 
± 0.07 (0 h), 1.86 ± 0.11 (12 h) and 4.88 ± 0.95% (24 h) of 
apoptotic cells were observed (Fig. 2D). Also, treatment 
with TET significantly decreased the expression level of 
the anti-apoptotic protein Bcl-xL in a concentration- 
dependent manner whereas the levels of the pro-apoptotic 
protein Bax remained unchanged (Fig. 3A). These tetradine- 
mediated effects on the apoptosis of A549 cells were 
clearly observed in time-course study. Treatment with 30 
μM of TET resulted in a significant increase in the levels of 
the pro-apoptotic proteins Bid and Bax whereas the 
expression levels of the anti-apoptotic protein Bcl-xL 
decreased in a time-dependent manner (Fig. 3B).
Since Akt is a crucial mediator of carcinogenesis and the 
phosphorylation of Akt is essential for its full activity and 
is involved in apoptosis [9], we have measured the potential 
effects of TET on Akt phosphorylation. TET treatment 
suppressed Akt phosphorylation at both Thr308 and Ser473 
in both time- and concentration-dependent manners, while 
the total Akt levels remained unchanged (Fig. 4). ERK is 
also known to be a pivotal factor in carcinogenesis and is 
closely associated with Akt signaling [19] and therefore 
the potential effects of TET treatment on ERK signaling 26    Hyun Sun Cho et al.
Fig. 4. The effect of tetrandrine (TET) on Akt activation in A549 
cells. The cells were treated with (A) various concentrations (0, 
10, 20 and 30 μM) of TET for 24 h or (B) 30 μM of TET for 
indicated times (0, 2, 4, 8, 12 and 24 h).
Fig. 5. The effect of tetrandrine (TET) on ERK activation in A549
cells. The cells were treated with (A) various concentrations (0, 
10, 20 and 30 μM) of TET for 24 h or (B) 30 μM TET for indicated
times (0, 2, 4, 8, 12 and 24 h).
Fig. 6. Flowcytometric detection of apoptosis in A549 cells. Cells
were treated with tetrandrine (TET) (30 μM) for 24 h in the absence
or presence of LY294002 (20 μM) or PD98059 (50 μM). (A) 
Control, (B) TET (30 μM), (C) TET (30 μM) + LY294002 (20 μM),
(D) TET (30 μM) + PD98059 (50 μM), (E) Summary of percentage
of apoptotic cells in the inhibitor study. Data are presented as mean
± SE of 3 independent experiments. **p ＜ 0.01.
were measured. Interestingly, TET also suppressed ERK 
phosphorylation in both time-/concentration- dependent 
manners similar to Akt phosphorylation (Fig. 5).
To characterize the relative roles of Akt and ERK on 
TET-induced apoptosis, two different selective inhibitors 
(LY294002 for PI3K pathway, PD98059 for MEK/ERK 
pathway) were used. TET alone increased apoptosis when 
compared to control (Figs. 6A, B and E). However, the 
fraction of apoptotic cells in samples co-treated with TET 
and the ERK inhibitor PD98059 was significantly increased 
compared to treatment with TET alone (Figs. 6D and E). 
Interestingly, cells co-treated with TET and the PI3K 
inhibitor did not manifest such synergetic effects (Figs. 6C 
and E). Our results strongly suggest that the inactivation of 
ERK may play an important role in TET-induced apoptosis. 
TET alone was enough to suppress the phosphorylation of 
Akt at both Ser473 and Thr 308 (Fig. 7) in both time-course 
as well as dose-response studies (Fig. 4). The expression of 
phosphorylated Akt was further suppressed by co-treatment 
with TET and LY294002 or PD98059 (Fig. 7). Very similar 
phenomena were found in terms of ERK phosphorylation 
(Fig. 7).
Discussion
Lung cancer is a major cause of cancer-related mortality 
worldwide. Lung cancer has proven difficult to control 
with conventional therapeutic and surgical approaches, 
and the prognosis is poor with an overall 5 year survival 
rate of 10-14% in the USA [11]. Therefore, it is clear that Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells    27
Fig. 7. The effects of a PI3K/Akt inhibitor and an MEK/ERK 
inhibitor on tetrandrine (TET)-treated A549 cells. The cells were
treated with TET (30 μM) for 24 h in the absence or presence of 
LY294002 (20 μM) or PD98059 (50 μM). Next, lysates were 
prepared and Western blot analysis was performed in order to 
determine protein expression levels.
novel and more effective treatments are needed to improve 
the outcome of therapy. In this respect, the use of naturally 
occurring or synthetic agents to prevent, inhibit or reverse 
lung carcinogenesis would greatly benefit public health. 
TET is a promising phytochemical agent that has recently 
attracted interest because of its cancer chemopreventive 
potential. In this study, TET, a candidate for use as a lung 
cancer chemopreventive agent, was characterized in the 
cell line A549.
Growing evidence has demonstrated that PI3K/Akt 
pathways are involved in several types of carcinogenesis. 
The activation of Akt causes malignant transformation in 
in vitro and in vivo mouse models of various human 
cancers [10]. In our study, TET suppressed Akt 
phosphorylation at Ser473 and Thr308 and inhibited lung 
tumorigenesis. The anti-tumor activity of TET appears to 
be mediated by the suppression of Akt phosphorylation 
because Akt requires phosphorylation of both Thr308 and 
Ser473 for full activity [24]. Our finding is clearly 
supported by previous reports that Akt activation is an 
early event in lung tumorigenesis [6], and that blocking 
Akt activity could suppress the progression of lung 
adenocarcinoma [12]. TET, therefore, may be an excellent 
lung cancer chemopreventive agent because one of the 
most promising molecules for chemoprevention and for 
the treatment of lung cancer targeting Akt.
Akt and ERK are both important signaling molecules that 
promote survival in different types of cancer. Spatiotemporal 
control of the ERK signal pathway is a key factor for 
determining the specificity of cellular responses including 
cell proliferation, cell differentiation and cell survival. The 
fidelity of this signaling is tightly regulated by docking 
interactions as well as scaffolding. The subcellular 
localization of ERK is controlled by cytoplasmic ERK 
anchoring proteins that have a nuclear export signal such as 
MEK. In quiescent cells, ERK localizes to the cytoplasm. 
In response to stimulation, activated ERK translocates to 
the nucleus [23]. To get detailed information about the 
relative roles of such signaling in lung cancer cell survival, 
the effect of treatment with TET and the PI3K inhibitor 
LY29294002 as well as the ERK inhibitor PD 98059 on the 
expression patterns of Akt within A549 cells was examined. 
TET treatment induced apoptosis and resulted in a 
decrease in Akt and ERK expression. PI3K inhibition had 
no clear synergistic effect on tetradrine-induced apoptosis, 
however, ERK inhibition resulted in a significant synergistic 
effect on apoptosis such that the degree of apoptosis was 
much higher than TET treatment alone and TET with PI3K 
inhibitor pretreatment. Western blot analysis of Akt and 
ERK protein levels and activation states confirmed that 
TET-induced apoptosis may occur under the dual action of 
ERK and Akt. Taken together, our results suggest that TET 
induces apoptosis and promotes the down-regulation of 
Akt expression in A549 lung cancer cells with a close 
relationship to ERK activity. Our results are further 
confirmed by other lines of evidence, which indicate that 
ERK regulates cell death in many cell lines. Increased 
levels and/ or the activation of ERK have been observed in 
a number of human cancer cell lines [8].
The evidence presented here suggests that TET 
deactivates Akt and synergistically promotes apoptosis 
through the inhibition of ERK. Such selective down- 
regulation of Akt activity and facilitating apoptosis 
indicates the potential utility of TET as a promising target 
for the prevention of lung cancer because Akt is likely to be 
an important factor in the early progression of lung 
carcinoma. The data presented provide evidence that TET 
selectively inhibits the proliferation of lung cancer cells by 
blocking Akt activation and that it facilitates apoptosis by 
ERK inhibition. Because Akt activity alters the sensitivity 
of non-small cell lung cancer cells to chemotherapeutic 
agents and irradiation [13], lung cancer treatment with 
TET may enhance the efficacy of chemotherapy and 
radiotherapy, and increase the apoptotic potential of lung 
cancer cells.
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